SB202190 (FHPI)

For research use only. Not for use in humans.

目录号：S1077

CAS No. 152121-30-7

SB202190 (FHPI)是一种有效的p38 MAPK抑制剂，靶向作用于p38α/β，无细胞试验中IC50为50 nM/100 nM，有时用于代替SB 203580研究其在体内对SAPK2a/p38的潜在作用。SB202190 可通过诱导自噬和血红素氧化酶1来抑制内皮细胞的凋亡。SB202190可显著抑制Erastin依赖的铁死亡ferroptosis。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1091.41	现货
25mg	RMB 1189.49	现货
100mg	RMB 3017.14	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的SB202190 (FHPI)发表文献118篇：

Immunity, 2021, S1074-7613(21)00210-7

PubMed: 34115964 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(6):577-582

PubMed: 28459450 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(11):1161-1167

PubMed: 27723727 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):428-36

PubMed: 23685672 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):316

PubMed: 33767160 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13046

PubMed: 34165921 ( click the link to review the publication )

Carcinogenesis, 2021, bgab002

PubMed: 33417668 ( click the link to review the publication )

Neoplasia, 2021, 23(1):129-139

PubMed: 33316537 ( click the link to review the publication )

Front Oncol, 2021, 11:657210

PubMed: 34026633 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(9)4463

PubMed: 33923316 ( click the link to review the publication )

Biosci Rep, 2021, 41(3)BSR20192668

PubMed: 33616153 ( click the link to review the publication )

J Mol Med (Berl), 2021, 10.1007/s00109-021-02047-5

PubMed: 33611659 ( click the link to review the publication )

Integr Biol (Camb), 2021, 13(6):139-152

PubMed: 33989405 ( click the link to review the publication )

Oncotarget, 2021, 12(9):878-890

PubMed: 33953842 ( click the link to review the publication )

Redox Biol, 2020, 28:101445

PubMed: 32037305 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):771

PubMed: 32943609 ( click the link to review the publication )

Cells, 2020, 13;9(5) pii: E1209

PubMed: 32414111 ( click the link to review the publication )

Cells, 2020, 28;9(4) pii: E822

PubMed: 32231153 ( click the link to review the publication )

J Neuroinflammation, 2020, 17(1):364

PubMed: 33261639 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:6584059

PubMed: 33274004 ( click the link to review the publication )

Cell Discov, 2020, 6:35

PubMed: 32550000 ( click the link to review the publication )
J Cell Mol Med, 2020, 24(5):3203-3216

PubMed: 32053272 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.201948363

PubMed: 32022930 ( click the link to review the publication )

Sci Rep, 2020,

PubMed: 32884042 ( click the link to review the publication )

Front Pharmacol, 2020, 11:758

PubMed: 32523533 ( click the link to review the publication )

Chem Biol Interact, 2020, 317:108944

PubMed: 31935364 ( click the link to review the publication )

Int J Environ Health Res, 2020, 10.1080/09603123.2020.1739236

PubMed: 32191530 ( click the link to review the publication )

Ann Surg Oncol, 2020, 10.1245/s10434-020-08790-2

PubMed: 32632882 ( click the link to review the publication )

J Thorac Dis, 2020, 12(7):3764-3773

PubMed: 32802455 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31753849 ( click the link to review the publication )

J Dev Biol, 2020, 8(3):E12

PubMed: 32660129 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0963-y

PubMed: 32606358 ( click the link to review the publication )

Cell Prolif, 2020, e12869

PubMed: 32597573 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, 10(4):779-796

PubMed: 32561494 ( click the link to review the publication )

Mol Cell, 2019, 76(6):965-980

PubMed: 31588023 ( click the link to review the publication )

Theranostics, 2019, 9(13):3879-3902

PubMed: 31281520 ( click the link to review the publication )

Theranostics, 2019, 9(17):5065-5084

PubMed: 31410202 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):718

PubMed: 31558705 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31248002 ( click the link to review the publication )

Cells, 2019, 8(9)

PubMed: 31461951 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29305

PubMed: 31612516 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )
Int J Mol Sci, 2019, 20(4)

PubMed: 30781441 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31117181 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19409

PubMed: 31857650 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 370(2):219-230

PubMed: 31189728 ( click the link to review the publication )

Life Sci, 2019, 231:116550

PubMed: 31185235 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105610

PubMed: 31518663 ( click the link to review the publication )

Mol Immunol, 2019, 111:162-171

PubMed: 31063937 ( click the link to review the publication )

J Biol Eng, 2019, 13:82

PubMed: 31709009 ( click the link to review the publication )

J Biol Eng, 2019, 13:36

PubMed: 31061676 ( click the link to review the publication )

Microb Pathog, 2019, 130:204-212

PubMed: 30885749 ( click the link to review the publication )

J Physiol Biochem, 2019, 75(4):475-487

PubMed: 31399951 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29511118 ( click the link to review the publication )

EBioMedicine, 2018, 36:497-507

PubMed: 30190207 ( click the link to review the publication )

Front Immunol, 2018, 9:1051

PubMed: 29896191 ( click the link to review the publication )

J Virol, 2018, 92(4)e01463-17

PubMed: 29167338 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):271-283

PubMed: 29090321 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5074

PubMed: 29568077 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Infect Immun, 2018, 22;86(9):e00233-18

PubMed: 29986890 ( click the link to review the publication )

Eur J Pharmacol, 2018, 838:129-137

PubMed: 30196111 ( click the link to review the publication )
Toxicon, 2018, 155:1-8

PubMed: 30290166 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2018, 5(3):333-352

PubMed: 29552622 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Biomaterials, 2017, 128:44-55

PubMed: 28288348 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)E2114

PubMed: 28991210 ( click the link to review the publication )

Sci Rep, 2017, 7:43242

PubMed: 28266583 ( click the link to review the publication )

Sci Rep, 2017, 7(1):7442

PubMed: 28785085 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 323:44-52

PubMed: 28341536 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 5(2):113-130

PubMed: 29693040 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 4(1):165-182

PubMed: 29204504 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

J Dent Res, 2016, 95(7):769-75

PubMed: 26961489 ( click the link to review the publication )

Int J Mol Sci, 2016,

PubMed: 27782092 ( click the link to review the publication )

Sci Rep, 2016, 6:30904

PubMed: 27485764 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 303:79-89

PubMed: 27174766 ( click the link to review the publication )

J Cancer, 2016, 7(8):900-9

PubMed: 27313779 ( click the link to review the publication )

J Diabetes Res, 2016, 2016:9073037

PubMed: 27635403 ( click the link to review the publication )

Oncol Rep, 2016, 35(5):3009-17

PubMed: 26986870 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )
Neurochem Res, 2016, 41(8):1969-81

PubMed: 27068033 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Oncotarget, 2016, 7(25):37407-37419

PubMed: 27270648 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(12):1578-90

PubMed: 26376801 ( click the link to review the publication )

Inflamm Bowel Dis, 2015, 21(3):496-506

PubMed: 25647156 ( click the link to review the publication )

Cell Transplant, 2015, 24(3):573-88

PubMed: 25654487 ( click the link to review the publication )

Nat Commun, 2014, 5:3479

PubMed: 24632940 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

BMC Cancer, 2014, 14:325

PubMed: ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Int Immunopharmacol, 2014, 24(1): 50-58

PubMed: 25479727 ( click the link to review the publication )

J Cell Biochem, 2014, 115(5):874-88

PubMed: 24375433 ( click the link to review the publication )

Cell Transplant, 2014, 23(4-5):641-56

PubMed: 24816456 ( click the link to review the publication )

Mol Biosyst, 2014, 10(3):605-12

PubMed: 24413303 ( click the link to review the publication )

Mol Cell Biochem, 2014, 397(1-2):131-8

PubMed: 25138701 ( click the link to review the publication )

Anticancer Agents Med Chem, 2014, 14(8):1154-60

PubMed: 24934165 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

产品安全说明书

p38 MAPK抑制剂选择性比较

生物活性

产品描述

特性

SB 202190 与SB 203580极为相似。

靶点

Ferroptosis ^[11] ()	p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
	50 nM	100 nM

体外研究

SB 202190显著抑制内源本底和和抗Fas抗体诱导的MAPKAPK 2活性，且抑制效果呈剂量依赖性。SB 202190本身就足以诱导Jurkat细胞和Hela细胞的死亡：通过激活CPP 32样半胱氨酸蛋白酶，可阻断Bcl - 2的表达。p38β可减轻而p38α可加剧由SB 202190诱导的细胞凋亡^[2]。在HaCaT细胞中SB 202190强烈抑制由紫外线诱导的cox - 2蛋白表达和 mRNA水平^[3]。用SB 202190处理肾小管上皮细胞（正常大鼠k肝脏-52E），可将由白蛋白引发的炎症（单核细胞趋化蛋白-1，MCP - 1）或肿瘤生长因子β-1（TGFβ-1）引发的原纤维化（原骨胶原I a1，procollagen-i alpha1）相关基因降低50%^[4]。SB 202190处理A549细胞，可诱导JNK磷酸化（该磷酸化效应呈时间和剂量依赖性）、转录因子ATF - 2磷酸化，并增加AP – 1与DNA的结合^[6]。SB 202190处理促进THP-1和MV4-11细胞的生长。SB 202190可提高c-Raf 和ERK（细胞外信号调节激酶）磷酸化，暗示由SB 202190诱导的白血病细胞增殖过程有Ras-Raf-MEK-mitogen激活的MAPK通路的参与^[7]。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT-116	NEO5NoRHfW6ldHnvckBCe3OjeR?=	MVWyOUDPxE1?	NYTRfmpoOzBibXnu	NHG2V4hFVVORwrC=	MWXheJRmdnWjdHXzJJRp\SCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25ib3[gbGJFNTJiaX6gdoV{eG:wc3n2[UB1dyCGQR?=	NUXJ[IRKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNlMzPTFpPkK2NlI{OjVzPD;hQi=>
MDA-MB-231	MUXGeY5kfGmxbjDBd5NigQ>?	MViyJO69VQ>?	NV6ye3FiOjRiaB?=		MWns[ZN{\W6nczDDR2wzKGmwZIXjeIlwdiCkeTDUUmbPuQ>?	MmHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMEC4OFgoRjJ4MUCwPFQ5RC:jPh?=
rBMSCs	M17od2Z2dmO2aX;uJGF{e2G7	MlnCNVAh\|ryP	M4HWVFIvPSCq		Mlf5[IVxemW\|c3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiRWLLJIFv\CCyM{i=	NFflenM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1N\|I3Pid-Mk[wOVMzPjZ:L3G+
MG63	NEfXOZZHfW6ldHnvckBCe3OjeR?=	M3jONlExNzJyL{OwJO69VQ>?	M1;S[VI1KGh?		NYrjfnZGe2mpbnnmbYNidnSueTDk[YNz\WG\|ZYOgeIhmKGyndnXsJI9nKHCqb4PwbI9zgWyjdHXkJJA{QCCrbnT1Z4VlKGK7IFPkR4wzKGmwIHGgZ49v[2WwdILheIlwdiBvZHXw[Y5l\W62IH3hco5meg>?	M{nFWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUm4N\|EzLz5{NUm5PFMyOjxxYU6=
MG63	NXvhb2t3SXCxcITvd4l{KEG\|c3H5	NFXGbWoyOC9{MD:zNEDPxE1?	NUPZSFBtOjRiaB?=		MX\zbYdvcW[rY3HueIx6KGSnY4LlZZNm\CC2aHWgZZBweHSxc3nzJJJifGVib3[gUWc3OyCrbnT1Z4VlKGK7IFPkR4wz	Mk\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7OUizNVIoRjJ3OUm4N\|EzRC:jPh?=
HTSMCs	MkDXSpVv[3Srb36gRZN{[Xl?	NUDRbYdmOC5zL{GvNVAh\|ryP	NI\ZOpEyKGh?		MkDZbY5pcWKrdHXkJGNQWk1vMj3pcoR2[2WmIFjPMVEheHKxdHXpckBt\X[nbIOgZY5lKG2UTlGg[ZhxemW\|c3nvci=>	NG\ZUIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmyNVQ3PCd-MkW5NlE1PjR:L3G+
MIA PaCa-2	NF;yemVHfW6ldHnvckBCe3OjeR?=	MVKyNOKh\|ryP	MnztNlQhcA>?		M1T0OpJm\HWlZXSgcIFkfGG2ZTDhZ4N2dXWuYYTpc44hcW5iY3;tZolv[XSrb36ge4l1cCCkb4ToJFIuTEdiYX7kJGQu[Wyub4PlxsA>	NYW1WXFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
MIA PaCa-2	MYnGeY5kfGmxbjDBd5NigQ>?	MUKyNOKh\|ryP	MUmyOEBp		NHj0UmZz\XO3bITzJIlvKGFibX;k[ZN1KGmwaHnibZRqd25ib3[gTGlHNTIQsTDwdo91\WmwIHHjZ5VufWyjdHnvci=>	NX;TR\|lKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
BxPC-3	Mm\ZSpVv[3Srb36gRZN{[Xl?	NGrNNFkzOMLizszN	NXLRNFJkOjRiaB?=		MnP3doV{fWy2czDpckBiKG2xZHXzeEBqdmirYnn0bY9vKG:oIFjJSk0y\|rFicILveIVqdiCjY3P1cZVt[XSrb36=	NXvDUphCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
AsPC-1	M1HTfWZ2dmO2aX;uJGF{e2G7	NInqcYMzOMLizszN	MoXTNlQhcA>?		NHHhXGhz\XO3bITzJIlvKGFibX;k[ZN1KGmwaHnibZRqd25ib3[gTGlHNTIQsTDwdo91\WmwIHHjZ5VufWyjdHnvci=>	NHjXTms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
MIA PaCa-2	Mln1SpVv[3Srb36gRZN{[Xl?	NF;RRo4zOMLizszN	M1fTSFI1KGh?		NFrIS2NmdmijbnPld{BkdGWjdnHn[UBw\iCSQWLQJJdp\W5iY3;tZolv\WRid3n0bEBodHWlb4PlJIFv[WyxZ4O=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6OES4PUc,OjV6OEi0PFk9N2F-
MIA PaCa-2	Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITHc3czOMLizszN	MYWyJIg>		M3[0UJNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	NGTGOGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
BxPC-3	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXTPIUzOMLizszN	NVu3V4dOOiCq		MUjz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6OES4PUc,OjV6OEi0PFk9N2F-
AsPC-1	NYHVNXZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvnNlDDqM7:TR?=	MluxNkBp		NWHsT3FEe2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	NHXnSm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
HEY	M2\xW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rnbVIxyqEQvF2=	MkTFNkBp		M3nHRZNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	NXL2Z\|NCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
OVCAR-3	NXTSVIozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LD[\|IxyqEQvF2=	M2mwTVIhcA>?		NUftRYo2e2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	MoW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEi0PFkoRjJ3OEi4OFg6RC:jPh?=
SK-OV-3	M3W5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TBN\|IxyqEQvF2=	NUjCfXBVOiCq		NYnKO2Zbe2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6OES4PUc,OjV6OEi0PFk9N2F-
MH7A	MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MY[yOEBp		M4S1bZJmcW6ob4Lj[ZMhfGinIHnubIljcXSxcomg[YZn\WO2czDv[kBZSU5?	M2\yeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OE[yPVY3Lz5{NUi2Nlk3PjxxYU6=
MH7A	MVfBdI9xfG:\|aYOgRZN{[Xl?	MXOyOUDPxE1?	NH7KV3gzPCCq		MoLydoV3\XK\|ZYOgZ4VtdCCleXPs[UBienKnc4SgbY5lfWOnZDDifUBZSU5iYX7kJINifXOnZDDhdI9xfG:\|aYOgc4Yh[2WubIOgeoliKGGldHn2ZZRqd25ib3[gTm5M	NXnzXZpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlI6PjZpPkK1PFYzQTZ4PD;hQi=>
SCC25	Mn3xSpVv[3Srb36gRZN{[Xl?	NH72VowzOCEQvF2=	M2njZVI1KGh?		NE\rd3hqdmO{ZXHz[ZMh[XW2b4DoZYd6KGyndnXs	NVTybG5{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODBpPkK1PFM1PDByPD;hQi=>
HaCaT	MoTGSpVv[3Srb36gRZN{[Xl?	MlXvOUDDvU1?	NVG1NYt{OjRiaB?=		NYX3T\|RQcW6qaXLpeJMhUU[QLd8zMYlv\HWlZXSgR2NNOjJicILv[JVkfGmxbjDs[ZZmdHN?	NGXqRms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFM2Oyd-MkW4N\|Q{PTN:L3G+
HaCaT	MUnGeY5kfGmxbjDBd5NigQ>?	M1;idlUhyrWP	Ml\0NlQhcA>?		NX76cHJScW6qaXLpeJMhUU[QLd8xMYlv\HWlZXSgR2NNOjJicILv[JVkfGmxbjDs[ZZmdHN?	NHjL[2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFM2Oyd-MkW4N\|Q{PTN:L3G+
HPAEpiCs	MlHvSpVv[3Srb36gRZN{[Xl?	NIWwZWoyNzNxMUCg{txO	M3uzW\|EhcA>?		NYPKdIVxemWmdXPld{BUOVBvaX7keYNm\CCLQ1HNMVEheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?=	MnXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5M{S5NFAoRjJ3N{O0PVAxRC:jPh?=
HPAEpiCs	MVXGeY5kfGmxbjDBd5NigQ>?	NYXMXYdJOS9\|L{GwJO69VQ>?	NEjtOnEyKGh?		MofrbY5pcWKrdIOgV\|FRNXO2aX31cIF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbjCgxsA>	M3:zR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{O0PVAxLz5{NUezOFkxODxxYU6=
HPAEpiCs	MUnGeY5kfGmxbjDBd5NigQ>?	MnzjNU8{NzFyIN88US=>	NHnuTG0yKGh?		MXTpcohq[mm2czDTNXAhfGmvZT3k[ZBmdmSnboTsfUB{fGmvdXzheIVlKGNvSoXuJJBpd3OyaH;yfYxifGmxbh?=	NVfDS2NWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3N\|Q6ODBpPkK1O\|M1QTByPD;hQi=>
K562	MlHmSpVv[3Srb36gRZN{[Xl?	MnT5NVDDqM7:TR?=	Mmr4NeKhcA>?	MV3EUXNQ	NELsT3hqdmirYnn0d{ByfWmwYXPybY5mNWmwZIXj[YQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u	M2jCVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nki0NFQ{Lz5{NU[4OFA1OzxxYU6=
PANC-1	NF3aVmxHfW6ldHnvckBCe3OjeR?=	MVmxNEDPxE1?	MY[xJIg>		NVH6fnBt\W6qYX7j[ZMhfGinIHH1eI9xcGGpaXOg[YZn\WO2wrC=	M1m4PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkOyNlIzLz5{NU[zNlIzOjxxYU6=
BxPC-3	NYjT[2xTTnWwY4Tpc44hSXO\|YYm=	MX[xNEDPxE1?	M{CwRVEhcA>?		M2LxO4VvcGGwY3XzJJRp\SCjdYTvdIhi\2mlIHXm[oVkfMLi	NF74fXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzOid-MkW2N\|IzOjJ:L3G+
K562	NXO1fGhNTnWwY4Tpc44hSXO\|YYm=	Mnj4NE4zPS1zIN88US=>	MXGyOEBp		NILxR\|V{fXCycnXzd4V{KHKnc4\ldoF1em:uLXnu[JVk\WRiSELBXEBxcG:\|cHjvdplt[XSrb36=	MoexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MUmzPVIoRjJ3NkG5N\|kzRC:jPh?=
THP-1	MYXGeY5kfGmxbjDBd5NigQ>?	NFLwcVk2KML3TR?=	Mn3hNkBp		M376PJNq\26rZnnjZY51dHliYYT0[Y52[XSnczDz[YNz\XSrb36gc4YhUUxvMd8xJIlv\HWlZXSgZpkhOjeRSFPoc4wheGy3czDGV2wuOcLi	NU\iVoJERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVg3PjFpPkK1OVk5PjZzPD;hQi=>
WB	MnLtSpVv[3Srb36gRZN{[Xl?	Mof5NlDjiIoQvF5CpC=>	MU[zNQKBkW2rbh?=		M3nGVoRm[3KnYYPld{B1cGViTGDTMUBweiCOVFGtbY5lfWOnZDDJUE03KGGwZDDUUmYu\|rIEoIDyc4R2[3Srb36=	NG\4R4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzNFY5Oid-MkW1N\|A3QDJ:L3G+
RAW 264.7	NWPQd3JRTnWwY4Tpc44hSXO\|YYm=	NH;rOYIyOMLizszN	MXGzNQKBkW2rbh?=		NHnQemVqdmS3Y3XzJINp[XKjY4Tldol{fGmlII\hZ5VwdGG2aX;uJI9nKE:Fc9Mg	MmeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkGzPVkoRjJ3NE[xN\|k6RC:jPh?=
RAW 264.7	NF7WbmJHfW6ldHnvckBCe3OjeR?=	NXX0OJozOTEEoN88US=>	M1vn[VMx6oDLbXnu		M1PIfYF1fGWwdXH0[ZMhfGinIHXm[oVkfHNib3[gU3BIKG:wIH;zeIVw[2yjc4SgdoV1emGldHnvci=>	M1PpSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[xN\|k6Lz5{NUS2NVM6QTxxYU6=
HaCaT	Mli1SpVv[3Srb36gRZN{[Xl?	MWO0NOKh\|ryP	NEDKV5k{NTJ2IHi=	M3jDVWROW09?	MYPy[YR2[2W\|IITo[UBi[2O3bYXsZZRqd25ib3[gXm8uOQ>?	NH\a[449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOVQ5PSd-MkW0N\|U1QDV:L3G+
H9c2	NEXyW\|lHfW6ldHnvckBCe3OjeR?=	M3HjeFUxyqEQvF5CpC=>	MoflNVIhcA>?		NHnZS3Fz\WS3Y3XzJGxFUCC{ZXzlZZNmKGGwZDDNUXAhdG:\|cx?=	NYfLOGNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFU5OThpPkK1NlQ2QDF6PD;hQi=>
HSCs	NVLVN2JSSXCxcITvd4l{KEG\|c3H5	NEe2N5ozPSEQvF2=	NVLqZYZuOjUEoHi=		NGrZTIx{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgWGcucW6mdXPl[EBi[3SrdnH0[YQhUFOFczDhdI9xfG:\|aYO=	NIjHWmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm2NVk2OCd-MkS5OlE6PTB:L3G+
THP-1	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnrTO\|IhcA>?	M3rj[2ROW09?	MoPkTWM2OD12LkhOwG0>	M4r1c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG1NFg4Lz5{NEixOVA5PzxxYU6=
MDDCs	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUfyZopRPzJiaB?=	Mn[1SG1UVw>?	MmHUTWM2ODJwN988US=>	NYfTW5ZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVUxQDdpPkK0PFE2ODh5PD;hQi=>
MDDCs	NYjCdWdLTnWwY4Tpc44hSXO\|YYm=	NGrHO3kxNTF3IN88US=>	NEjzenQ1QCCq	MoP2SG1UVw>?	NEm1e3J{fXCycnXzd4V{KEmITj5OtUBidmRiSWCtNVAheHKxZIXjeIlwdsLi	NV3LNWhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVUxQDdpPkK0PFE2ODh5PD;hQi=>
MDDCs	MX7GeY5kfGmxbjDBd5NigQ>?	NVPkZnpnOC1zNTFOwG0>	M3[4SlQ5KGh?	MlzaSG1UVw>?	MXPpcohq[mm2czDNTXAuOWFuIF3JVE0y[iCjbnSgVmFPXEWVIIDyc4R2[3Srb36=	MknkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUWwPFcoRjJ2OEG1NFg4RC:jPh?=
MDDCs	NHrSXJhHfW6ldHnvckBCe3OjeR?=	NGruRWsyOCEQvF2=	NUjNXlJCOy53IHi=	NIjJToVFVVOR	MW\icI9kc3NiRVLPWkBIWCxiYoX0JI5wfCCYU2[gS{Bu\WSrYYTl[EBmdnS{eTDpcpRwKGi3bXHuJG1FTEO\|	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhzNUC4O{c,OjR6MUWwPFc9N2F-
macrophages	NEPmWXJHfW6ldHnvckBCe3OjeR?=	M1n6UFHjiIoQvF2=	MYO0MlXjiImq		M1rrXoNwdXCuZYTlcJkhcW6qaXLpeJMhVVRvSVnJMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCQRj5OvmI>	NHnzN3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwPFY{Oyd-MkS4NFg3OzN:L3G+
PDL	MmL3SpVv[3Srb36gRZN{[Xl?	M{m3VlIxyqEQvF5CpC=>	MnXqN\|AhdWmw	Mm\tSG1UVw>?	MnX3d4lodmmoaXPhcpRtgSCrbnjpZol1eyC2aHWgeIVve2muZTDmc5Jk\S2vZXTpZZRm\CCETWCtNkBmgHC{ZYPzbY9v	M1XsR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[xNFgyLz5{NEW2NVA5OTxxYU6=
AGS	MYjGeY5kfGmxbjDBd5NigQ>?	NX6zc4x[PSEQvF2=	MkfIN\|AhdWmw		MVrzeZBxemW\|c3XzxsAyNWmwZIXj[YQh[2G\|cHHz[U05KGGwZDDjZZNx[XOnLUOgZYN1cX[jdHnvci=>	M3ntcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUS3PFc5Lz5{NEW0O\|g4QDxxYU6=
H520	MVjGeY5kfGmxbjDBd5NigQ>?	M1fIUFExyqEEtV2=	M2\o[lEhcA>?	NX7xSVZkTE2VTx?=	M{HSW4Rm[3KnYYPld{B1cGVicHXt[ZRz\XinZD3pcoR2[2WmIF3TTFIhdVKQQTDhcoQheHKxdHXpckBt\X[nbIO=	MlXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3M{C0O\|UoRjJ2NUOwOFc2RC:jPh?=
H1703	MXzGeY5kfGmxbjDBd5NigQ>?	NHfyNG4yOMLiwsXN	NFraTW8yKGh?	NG\qeGVFVVOR	NVXCd4JC\GWlcnXhd4V{KHSqZTDw[Y1mfHKneHXkMYlv\HWlZXSgUXNJOiCvUl7BJIFv\CCycn;0[YlvKGyndnXsdy=>	M2H3TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUOwOFc2Lz5{NEWzNFQ4PTxxYU6=
H520	NVTPOVQ2TnWwY4Tpc44hSXO\|YYm=	MVSxNOKhyrWP	MWmxNkBp	Mmm2SG1UVw>?	NH;LendqdmirYnn0d{Bx\W2ndILlfIVlNWWuaXPpeIVlKE2VSEKgdJJwfGWrbjDzeIFjcWyrdIm=	Mnz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3M{C0O\|UoRjJ2NUOwOFc2RC:jPh?=
H1703	NV36PHpsTnWwY4Tpc44hSXO\|YYm=	NHXlT\|gyOMLiwsXN	MlvONVIhcA>?	NWTYNY5lTE2VTx?=	MmLKbY5pcWKrdIOgdIVu\XS{ZYjl[E1mdGmlaYTl[EBOW0h{IIDyc5RmcW5ic4ThZoltcXS7	M3L4TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUOwOFc2Lz5{NEWzNFQ4PTxxYU6=
H520	NFXOd2ZHfW6ldHnvckBCe3OjeR?=	M3fieVExyqEEtV2=	MYC2JIg>	NEn2cHBFVVOR	Mn3wd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV\|MES3OUc,OjR3M{C0O\|U9N2F-
H1703	Mn73SpVv[3Srb36gRZN{[Xl?	MljDNVDDqML3TR?=	NH3Q[FY3KGh?	MWLEUXNQ	Mn\Zd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n	NUPzU4tMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1N\|A1PzVpPkK0OVMxPDd3PD;hQi=>
MC3T3-E1	M1XNcWZ2dmO2aX;uJGF{e2G7	NInJbZoxNjNxMz:zNEDPxE1?	MoLmNUBp		MkS4ZZR1\W63YYTld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCneIDy[ZN{cW:wIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{wrC=	NYrncW1zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NFI3QTZpPkK0OVAzPjl4PD;hQi=>
MC3T3-E1	NHnHNGRHfW6ldHnvckBCe3OjeR?=	M4PqeVMxKM7:TR?=	MUixJIg>		M1rXbYF1fGWwdXH0[ZMhXE6ILd8xMZN1cW23bHH0[YQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u	M{W4clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUCyOlk3Lz5{NEWwNlY6PjxxYU6=
HUVECs	NGO2cVNHfW6ldHnvckBCe3OjeR?=	NW\Pc3BvOTEEoNM1US=>	MlTRNUBp		NED1cW5qdmirYnn0d{BVVkZvzsGtbY5lfWOnZDDDXGNNOSCycn;keYN1cW:w	NUC1c5MyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFc6PjRpPkK0OFg4QTZ2PD;hQi=>
AGS	NE\MRoFHfW6ldHnvckBCe3OjeR?=	NYLO[plsOTEEoNM1US=>	NVi5VGpvOzEEoH3pci=>		M{\ZcYlvcGmkaYTzJGlNNTIQsj3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OU[4NUc,OjR2N{m2PFE9N2F-
MKN-45	NVmwVWtPTnWwY4Tpc44hSXO\|YYm=	NWjremxFOTEEoNM1US=>	MoHTN\|DDqG2rbh?=		NVKxUlBlcW6qaXLpeJMhUUxvMd8yMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{i=	M4LYOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe5OlgyLz5{NES3PVY5OTxxYU6=
AGS	MkHUSpVv[3Srb36gRZN{[Xl?	NYCzeVhQOTEEoNM1US=>	M1n5TVMxyqCvaX6=		MkfwZZR1\W63YYTld{BKVC1zzsKtbY5lfWOnZDDHRUBk\WyuIH3p[5JifGmxbjDhcoQhcW64YYPpc44>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OU[4NUc,OjR2N{m2PFE9N2F-
MKN-45	M2j6b2Z2dmO2aX;uJGF{e2G7	M1jr[lExyqEEtV2=	MVezNOKhdWmw		NUTLe3dn[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25?	M3rweVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe5OlgyLz5{NES3PVY5OTxxYU6=
AGS	NU\1e5hHTnWwY4Tpc44hSXO\|YYm=	NGfTd4cyOMLiwsXN	M3v3WFMxyqCvaX6=		MoXrd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiSXytNe6zNWmwZIXj[YQhVU2SMjDhcoQhVU2SOTDtVm5CKGW6cILld5Nqd25?	NXrjcGxNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|k3QDFpPkK0OFc6PjhzPD;hQi=>
MKN-45	NXq5OYw5TnWwY4Tpc44hSXO\|YYm=	MnLENVDDqML3TR?=	MVuzNOKhdWmw		MYTzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCLbD2x{tIucW6mdXPl[EBOVVB{IHHu[EBOVVB7IH3SUmEh\XiycnXzd4lwdg>?	MlvMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{m2PFEoRjJ2NEe5OlgyRC:jPh?=
DCs	MXnGeY5kfGmxbjDBd5NigQ>?	Mmq5NlDDqM7:TR?=	M{GyR\|HDqGh?		MYTk[YNz\WG\|ZYOgTWwuOTJicILv[JVkfGmxbh?=	NUPYN\|dCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N\|Q3OzZpPkK0OFM1PjN4PD;hQi=>
HUVEC	NITJPXFHfW6ldHnvckBCe3OjeR?=	M4H0[VIxKM7:bdMg	M37SWVUhcA>?	M3LQemROW09?	NELqPWVz\WS3Y3XzJIN6fG:taX7lJIV5eHKnc4Ppc44hdGW4ZXzzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy	M{C3SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUi5NFYzLz5{NEG4PVA3OjxxYU6=
A 549	Ml7kSpVv[3Srb36gRZN{[Xl?	M3u4RVUxKM7:TR?=	NWflRY5QOSCq		MnKw[IVkemWjc3XzJJRp\SCuZY\lcEBw\iCLTD24xsA>	NH3OfGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3PVY5QCd-MkSxO\|k3QDh:L3G+
H520	Ml[ySpVv[3Srb36gRZN{[Xl?	M2O0RVUwOTBizszN	MnSwNUBp	MW\EUXNQ	MVfk[YNz\WG\|ZYOgUXNJOiCycn;0[YlvKGG\|IIflcIwh[XNibWLORUBt\X[nbIOgbY4h\2WoaYTpcoljNWW6cH;z[YQh[2WubB?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|OEmwN{c,OjRzM{i5NFM9N2F-
H1703	MXvGeY5kfGmxbjDBd5NigQ>?	MX[1M\|ExKM7:TR?=	M2TaUlEhcA>?	M37KVmROW09?	MnLF[IVkemWjc3XzJG1UUDJicILveIVqdiCjczD3[YxtKGG\|IH3SUmEhdGW4ZXzzJIlvKGenZnn0bY5q[i2neIDvd4VlKGOnbHy=	NXz2NGJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|g6ODNpPkK0NVM5QTB\|PD;hQi=>
H520	NFTvNppHfW6ldHnvckBCe3OjeR?=	MlSwNVDDqML3TR?=	M2fhSFEzKGh?	M4TifmROW09?	NH\2UVRl\WO{ZXHz[ZMhVVOKMjDtVm5CKGGwZDDwdo91\WmwIIP0ZYJqdGm2eTDpckBo\W[rdHnubYIufHKnYYTl[EBPW0OOQzDj[Yxtew>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|OEmwN{c,OjRzM{i5NFM9N2F-
H1703	NXPkflVjTnWwY4Tpc44hSXO\|YYm=	M{DOXVExyqEEtV2=	NU[wfW85OTJiaB?=	Ml[xSG1UVw>?	NIDGWZRl\WO{ZXHz[ZMhVVOKMjDtVm5CKGGwZDDwdo91\WmwIIP0ZYJqdGm2eTDpckBo\W[rdHnubYIufHKnYYTl[EBPW0OOQzDj[Yxtew>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|OEmwN{c,OjRzM{i5NFM9N2F-
MCF-7	Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDxb2EyOMLizszN	MUCyOOKhcA>?		MlXlbY5pcWKrdIOgeIhmKEOUMUC4MYlv\HWlZXSgZ4VtdCCmZXH0bC=>	MnPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMki4OVMoRjJ2MUK4PFU{RC:jPh?=
HPAEpiCs	M{njTGZ2dmO2aX;uJGF{e2G7	NVrVfGNZOC5zL{GvNVAh\|ryP	M4PF[\|EhcA>?		MVPpcohq[mm2czDUUmYu\|rFvaX7keYNm\CClUFzBNuKheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9v	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4OUG1PEc,OjRyNkmxOVg9N2F-
podocytes	M1X0V2Z2dmO2aX;uJGF{e2G7	NYL2dYhnOTEEoN88US=>	NUDLbpFYOSCq		M320WIlvcGmkaYTzJHRITs7{MT3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6TVHQT{BidmRiRYLrNU8zyqB?	M4SxRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEO2NlEzLz5{NECzOlIyOjxxYU6=
MCF-7	NXvsSJV1TnWwY4Tpc44hSXO\|YYm=	MnfFNVDDqM7:TR?=	MXexJIg>	NVLGZnVxTE2VTx?=	NUXRNJM4emWmdXPld{B1cGViV1GtbY5lfWOnZDDwbI9{eGixconsZZRm\CCyM{igUWFRUw>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzOUC5NEc,OjRyMUmwPVA9N2F-
MCF-7	MWrGeY5kfGmxbjDBd5NigQ>?	M4rBSFExyqEQvF2=	NEnqdmszPCCq	MXjEUXNQ	NIj5eZpqdmO{ZXHz[ZMhfGinIGfBMYlv\HWlZXSgZZBweHSxc3nz	M{f4WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG5NFkxLz5{NECxPVA6ODxxYU6=
HAPI	M{TjVGZ2dmO2aX;uJGF{e2G7	NVnNZ3JQOTBxMkCvOFDDqM7:TR?=	Mn;tNUBp		M1HWS4lvcGmkaYTzJHRETERvaX7keYNm\CCyM{ivTm5MKE2DUFugdIhwe3Cqb4L5cIF1cW:w	NUHuVXJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlkyOjBpPkKzPVY6OTJyPD;hQi=>
HAPI	NUXpRVBnTnWwY4Tpc44hSXO\|YYm=	M3PrTFIxyqEQvF5CpC=>	NFu5d5IyKGh?	NX7kcIRrTE2VTx?=	MVfheJRmdnWjdHXzJHRETERvaX7keYNm\CCjY4TpeoF1cW:wIH;mJIlPV1NiYX7kJJBzd2S3Y4Tpc44>	M4LWbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[5NVIxLz5{M{m2PVEzODxxYU6=
HepG2	MoP1SpVv[3Srb36gRZN{[Xl?	NViwSm53OzVyIH7N	MoSwNlQhcA>?		MWfpcohq[mm2czD0bIUh\GWpdXXsbY4ucW6mdXPl[EBi[3SrdnH0bY9vKG:oIICzPG1CWEt?	NUfyb5VoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|MyQThpPkKzPVM{OTl6PD;hQi=>
AGS	M{Ha[GZ2dmO2aX;uJGF{e2G7	M3L6TlExyqEQvF2=	M2fQPFMxKG2rbh?=		MYHpcohq[mm2czDjZZNx[XOnLUOgZYN1cX[jdHnvckBidmRiaX7obYJqfGmxbjDv[kBGWkt?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3MEm5OEc,OjN6NUC5PVQ9N2F-
HepG2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTCNE02OCEQvF2=	Mn\QOFghcA>?		M3fKRYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NISwUW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iwO\|UxQCd-MkO4NFc2ODh:L3G+
BEL7404	NX2xZnZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml75NE02OCEQvF2=	Mmm5OFghcA>?		M1LOOolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NGHvSI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iwO\|UxQCd-MkO4NFc2ODh:L3G+
HL7702	NF[wXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;k[VAxNTVyIN88US=>	NH3SWFU1QCCq		MUjpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhyN{WwPEc,OjN6MEe1NFg9N2F-
HepG2	NYXvOG5YTnWwY4Tpc44hSXO\|YYm=	NFHjcpExNTVyIN88US=>	M1fzPFI1KGh?		M13pcolvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZicEO4JIRwf26\|dILlZY0heHKxdHXpcpMhVUGSS1HQT\|ItKEGWRkKsJG1UUzFiYX7kJGhUWDJ5IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NVTCNWtJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NFc2ODhpPkKzPFA4PTB6PD;hQi=>
BEAS-2B	MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjPU2Z{OTBizszN	MkfSN\|AhdWmw		NF3Oeplz\X[ncoPld{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliaX7keYNm\CCkeTDIR2k>	NGX4XlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4OFA{PCd-MkO3PFQxOzR:L3G+
BEAS-2B	MonOR5l1d3SxeHn0fUBCe3OjeR?=	MX6xNEDPxE1?	NIW3UIg{OCCvaX6=		M{LjfYlvcGmkaYTl[EB1cGViaX7jdoVie2ViaX6gUGRJKGGwZDDJUE05KGW6cILld5Nqd25?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd6NECzOEc,OjN5OESwN\|Q9N2F-
BEAS-2B	M4X3SGZ2dmO2aX;uJGF{e2G7	MnHhNVAh\|ryP	NYLmO2QzOzBibXnu		NW\tU3R6\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ4F{eGG\|ZT2zMEBD[WRiYX7kJIZiew>?	NUPxZ3pnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3PFQxOzRpPkKzO\|g1ODN2PD;hQi=>
H9c2	NE\BbIlHfW6ldHnvckBCe3OjeR?=	MoPQNE4xOS9yLkGvNUDPxE1?	NE[5VnAyKGh?		M2n3eoF1fGWwdXH0[ZMhXE6ILd8xMYlv\HWlZXSgUW1RNTliZYjwdoV{e2mxbjygcXJPSSCuZY\lcJMtKGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd5NEK1Nkc,OjN5N{SyOVI9N2F-
H9c2	Ml3NSpVv[3Srb36gRZN{[Xl?	NHLLPWgyKM7:TR?=	M1v0blEhcA>?		Mn;hdoVlfWOnczDUUmYu\|rFiZHny[YN1dHlic4TpcZVt[XSnZDDwN\|ghVUGSSzDwbI9{eGixconsZZRqd25?	Mlr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5N{SyOVIoRjJ\|N{e0NlUzRC:jPh?=
U937	NXLMSGZmTnWwY4Tpc44hSXO\|YYm=	NXzYfZE6OTEEoN88UeKh	MYSxJIg>		NFn3[W1i[nKxZ3H0[ZMhfGinIHPh[oZmcW6nIHXm[oVkfCCxbjDNT3AuOSCjbnSgVHAzSWQQsTDtVm5CKHS{YX7zZ5JqeHSrb37hcEBt\X[nbIO=	M2\MWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C3N\|g4Lz5{M{ewO\|M5PzxxYU6=
U937	MXvGeY5kfGmxbjDBd5NigQ>?	M2PyWFExyqEQvF5CpC=>	NX75fmszOSCq		M2\6R4Fjem:pYYTld{Bk[W[oZXnu[U1qdmS3Y3XkJG1MWC1zIHTve44uemWpdXzheIlwdiCjbnSgVHAzSWQQsTD1dE1z\We3bHH0bY9v	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyN{O4O{c,OjN5MEezPFc9N2F-
U937	NIDiXpNHfW6ldHnvckBCe3OjeR?=	MX:xNOKh\|ryPwrC=	NUjRbG1ZOSCq		M1vqRZN2eHC{ZYPz[ZMh[y2MdX6gZY5lKEOURVKgdIhwe3Cqb4L5cIF1cW:wIHnuJINi\m[naX7lMZRz\WG2ZXSgZ4VtdHQEoB?=	NIO1U2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewO\|M5Pyd-MkO3NFc{QDd:L3G+
A549	MXXGeY5kfGmxbjDBd5NigQ>?	NHr4S5cxNjNxMz:zNEDPxE1?	MkP6NUBp		MlvRd4lodmmoaXPhcpRtgSCjdITlcpVifGW\|IFHUVO6{Wy2vZXTpZZRm\CCFT2itNkBxem:2ZXnuJIFv\CCvUl7BJIV5eHKnc4Ppc44h[W6mIIDyc41wfGW{IHHjeIl3cXS7wrC=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6ME[3OEc,OjN4OEC2O\|Q9N2F-
A549	MlPOSpVv[3Srb36gRZN{[Xl?	NH;GUIYyOMLizszNxsA>	MknINE0{OCCvaX6=		NFvrS5JqdmirYnn0d{BCXFEQs2OgbY5lfWOnZDDwOFIweDR2IF3BVGsh[W6mIICzPEBOSVCNIIDoc5NxcG:{eXzheIlwdg>?	MmD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OEC2O\|QoRjJ\|NkiwOlc1RC:jPh?=
A549	MULGeY5kfGmxbjDBd5NigQ>?	NVXmTGg1OTEEoN88UeKh	M3qzSVEhcA>?		MY\pcohq[mm2czDBWHDPu1NiaX7keYNm\CCQRj5OvmIheDZ3IIP1ZpVvcXRicHjvd5Bpd3K7bHH0bY9vKGGwZDDOSk3PwkJicILvcY91\XJiYXP0bZZqfHl?	NHHYclQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NFY4PCd-MkO2PFA3PzR:L3G+
A549	M2PzR2Z2dmO2aX;uJGF{e2G7	NYDENVBVOTEEoN88UeKh	MmD4NUBp		NEXBeHFz\WS3Y3XzJGFVWM7\|Uz3zeIlufWyjdHXkJINRVEF{IIDoc5NxcG:{eXzheIlwdsLi	NVLw[Wp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFA3PzRpPkKzOlgxPjd2PD;hQi=>
A549	MnLUSpVv[3Srb36gRZN{[Xl?	M1;uVlExyqEQvF5CpC=>	M{jyclEhcA>?		M2\KTJJm\HWlZYOgRXRR\|rOVLXXubIFv[2WmIHXufplu[XSrYzDhZ5Rqfmm2eTDv[kBkWEyDMtMg	NGrXfFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NFY4PCd-MkO2PFA3PzR:L3G+
PC12	NFrLSGpHfW6ldHnvckBCe3OjeR?=	M4HEblExNzJyL{SwJO69VQ>?	NEPuWmgyyqCq		MnL6bY5pcWKrdIOgTm5MKGGwZDDwN\|g>	M3;BfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUi0N\|U4Lz5{M{W4OFM2PzxxYU6=
HK-2	NU\SfWtRSXCxcITvd4l{KEG\|c3H5	MnTBNlDDqM7:TR?=	M2jIO\|I1KGh?		NHmycpJqdmirYnn0d{BGWktiYX7kJJA{QE2DUFu=	NEDWdYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0N\|E2OSd-MkO1OFMyPTF:L3G+
H9c2	M4HVZ2Z2dmO2aX;uJGF{e2G7	MUixxsDPxE1?	MoniNUBp		NFjxb29z\WS3Y3XzJHRPTi4QsT3pcoR2[2WmIF3NVE06KG2UTlGgcIV3\Wy\|IHHu[EBxem:vb4TldkBi[3Srdnn0fS=>	M2m4ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{WzOlk6Lz5{M{O1N\|Y6QTxxYU6=
H9c2	M{fq[2Z2dmO2aX;uJGF{e2G7	Mn;ZNeKh\|ryP	NVPzbmxQOSCq		MVPy[YR2[2W\|IGTOSk3PuS2nbnjhcoNm\CCDUD2xJJBzd22xdHXyJIFkfGm4aYT5	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN3M{[5PUc,OjN\|NUO2PVk9N2F-
H1650	M4XR[GZ2dmO2aX;uJGF{e2G7	M3XkVVExyqEQvF5CpC=>	M2Xnc\|EhcA>?	NV21NVhQTE2VTx?=	Mljs[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR\|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>?	MlS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Mki2PVYoRjJ\|MkK4Olk3RC:jPh?=
H1703	MVzGeY5kfGmxbjDBd5NigQ>?	MXexNOKh\|ryPwrC=	M1TL[VEhcA>?	Mmr3SG1UVw>?	MkfY[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR\|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>?	NYe1NlN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNlg3QTZpPkKzNlI5Pjl4PD;hQi=>
H1650	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXP6WXp3OTEEoN88UeKh	MWqxJIg>	M37jUGROW09?	NWPMfGFQ\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?=	NUnyTW45RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNlg3QTZpPkKzNlI5Pjl4PD;hQi=>
H1703	Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVWxNOKh\|ryPwrC=	MVKxJIg>	NFLNeldFVVOR	NVX0OZJu\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?=	NICyVVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KyPFY6Pid-MkOyNlg3QTZ:L3G+
medulloblastoma cells	NEOwcpJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				NXjPZ2lpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDt[YR2dGyxYnzhd5RwdWFiY3XscJMhcGG{Yn;ybY5oKGindHXyc5p6\2:3czDweINpOSCpZX7lJIJ6KE2WVDDhd5NigSxiRVO1NEA:KDNwMEC2JO69VS5?	M3PmTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEG3OlMyLz5zN{SxO\|Y{OTxxYU6=
neural precursor cells	MmXtRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				MknwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCwZYXyZYwheHKnY4Xyd49zKGOnbHzzJIJ6KE2WVDDhd5NigSxiRVO1NEA:KDhwME[zJO69VS5?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzN{[zNUc,OTd2MUe2N\|E9N2F-
RAW264.7	NX:5XXRnSW62aXnu[oxidW2jdH;yfUBie3OjeR?=		MnWyNVAhdWmwcx?=		NInCUYdCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgUm8heHKxZIXjeIlwdiCrbnP1ZoF1\WRiZn;yJFExKG2rboOgdJJqd3JidH:gUHBUNWOqYXzs[Y5o\SCvZXHzeZJm\CCjZoTldkAyQCCqcoOgZpkhT3KrZYPzJI1mfGixZDygTWM2OCB;IEG2JO69VS5?	MonDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{G3PVgoRjJ{OEOxO\|k5RC:jPh?=
BL21(DE3)	M3zCeGZ2dmO2aX;uJIF{e2G7		NIjGNpU3OCCvaX7z		Ml72TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFjpd\|YufGGpZ3XkJGJTTDRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSiGRUOpJINmdGy\|IIXzbY5oKGKrb4Tpcplt[XSnZDDobZN1d26nIFi0JJBmeHSrZHWgZZMhe3Wkc4TyZZRmKGGodHXyJFYxKG2rboOgZpkhSWyyaHHTZ5Jm\W5iYYPzZZktKEmFNUCgQUA{NjRizszNMi=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF7NUeyN{c,OjhzOUW3NlM9N2F-
RAW264.7	M3r3eGZ2dmO2aX;uJIF{e2G7				NWe4O5EzWHKxdHXjeIlwdiCjZ3HpcpN1KEKjY3nscJV{KGGwdHjyZYNqeyCycn;0[YN1cX[nIHHueIlo\W5iYX7kJIxmfGijbDD0c5hqdi2maYDoeIhmemmjIITvfIlvKGOqaX3ldolkKHC{b4TlbY4hdWWmaXH0[YQh[3m2b4TvfIlkcXS7IHnuJI1wfXOnIGLBW\|I3PC55IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6	NXHFUHFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0PFU2ODRpPkG3OFg2PTB2PD;hQi=>
A673	Mmm5dWhVWyCjc4PhfS=>				NYi4VZBDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	M4rWXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	NV63ZWE6eUiWUzDhd5NigQ>?				NEPFbYhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	NU[3ZXN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	MV3xTHRUKGG\|c3H5				MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	NGTvS4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MkK3dWhVWyCjc4PhfS=>				NVficXNmeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	M3jLeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	NUfJZoVTeUiWUzDhd5NigQ>?				MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0yOiClZXzsdy=>	M{Xh[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MVXxTHRUKGG\|c3H5				NIrsS5hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>?	MkHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	MmLkdWhVWyCjc4PhfS=>				NHjF[XpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	MojtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	M1jjSpFJXFNiYYPzZZk>				NX;BfHVteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	NVX5SVBORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	NFH0TFByUFSVIHHzd4F6				MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{	MkHBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	MXHxTHRUKGG\|c3H5				NVX1b2JEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	MnqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	NIjUdnVyUFSVIHHzd4F6				M{PLcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	MlXGdWhVWyCjc4PhfS=>				NHvifHZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	M{HPU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	MmLtdWhVWyCjc4PhfS=>				NHrxUllyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDNyIHPlcIx{	M3niWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	M3u5eZFJXFNiYYPzZZk>				MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDPTHMuPTBiY3XscJM>	M{\TWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MW\xTHRUKGG\|c3H5				NFvoeYhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	M{LK[5FJXFNiYYPzZZk>				NHHjPJFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	NGHPbZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MWPxTHRUKGG\|c3H5				MmHwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR\|IHPlcIx{	NWHSOoJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	NWTMcHROeUiWUzDhd5NigQ>?				NXHMR3JqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NH62UIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NV:zRXBpeUiWUzDhd5NigQ>?				Ml7DdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtew>?	M1ux[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	M4nXVJFJXFNiYYPzZZk>				NYO5PWNPeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	NVTHd4ZTeUiWUzDhd5NigQ>?				NHPQdJlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDF6IHPlcIx{	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; PubMed: 26844273 EBioMedicine CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. pJNK1 / pJNK2 / JNK1 / JNK2 ; PubMed: 18222647 Cell Signal A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described.	26844273 18222647
Immunofluorescence	p-p38 / MMP9; PubMed: 24479681 Mol Cancer Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.	24479681
Growth inhibition assay	Cell viability ; PubMed: 26844273 EBioMedicine Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).	26844273

体内研究

SB 202190通过抑制p38减弱了由人脊髓灰质炎IgG（PV-IgG）在被动转移小鼠模型中诱发的水泡形成^[5]。在脓毒症内毒素模型中，与对照组相比，经SB 202190处理可显著提高存活率^[8]。

激酶实验： ^[1]	- 合并体外酶活检测: p38α 和 p38β 溶解在25mM的Tris - HCl缓冲液中，PH 7.5，含0.1mM EGTA，髓鞘碱性蛋白（0.33毫克/毫升）作为底物。人工操作条件用50μL [γ-³³P]ATP于30 °C孵育10分钟；Biomek 2000自动化工作站用25μL [γ-³³P]ATP在96孔板室温孵育40分钟。ATP和乙酸镁浓度分别为0.1mM和10mM。所有检测都用MgATP起始。人工检测将孵育液滴到磷酸纤维素纸上，浸泡在50mM磷酸中。用5μL磷酸终止反应，后将孵育液点滴在P30过滤垫上。滤膜在50mM磷酸中漂洗四次以去除ATP，在用丙酮（人工孵育）或甲醇（工作站孵育）处理后，干燥并用放射性计量。
细胞实验： ^[2]	- 合并 Cell lines: Jurkat, 和 HeLa细胞 Concentrations: 溶解于DMSO, 终浓度~50 μM Incubation Time: 24 小时 Method: 细胞血清饥饿后，用不同浓度SB 202190处理24小时。用台盼蓝或PI染色后经流式细胞仪分析，以检测细胞活力。凋亡细胞核用H33258染色。 (Only for Reference)
动物实验： ^[5]	- 合并 Animal Models: C57BL/6J 小鼠皮内注射无菌的对照IgG或人脊髓灰质炎IgG做对比。 Dosages: 12.5 μg Administration: 皮内注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	66 mg/mL (199.19 mM)
	Ethanol	12 mg/mL (36.21 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%H2O	8 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download SB202190 (FHPI) SDF

分子量	331.34
化学式	C₂₀H₁₄N₃OF
CAS号	152121-30-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

选择性强的p38 MAPK抑制剂

BIRB 796 (Doramapimod) : p38α-selective, Kd=0.1 nM.
活性最高的p38 MAPK抑制剂

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
用于临床的p38 MAPK抑制剂

VX-702 : Phase II for Rheumatoid Arthritis.
最新的p38 MAPK抑制剂

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

研究领域

产品类型

定制您的化合物库

SB202190 (FHPI)

客户使用Selleck生产的SB202190 (FHPI)发表文献118篇：

产品安全说明书

p38 MAPK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download SB202190 (FHPI) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

相关p38 MAPK产品